Cancer nanotheranostics : : what have we learned so far? / / edited by João Conde, Pedro Viana Baptista, Jesús M. De La Fuente and Furong Tian.
After a quarter of century of rapid technological advances, research has revealed the complexity of cancer, a disease intimately related to the dynamic transformation of the genome. However, the full understanding of the molecular onset of this disease is still far from achieved and the search for m...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
TeilnehmendeR: | |
Place / Publishing House: | [Lausanne, Switzerland] : : Frontiers Media SA,, [2015] ©2015 |
Year of Publication: | 2016 2015 |
Language: | English |
Series: | Frontiers research topics.
|
Physical Description: | 1 online resource (128 pages) :; illustrations (chiefly colour); digital file(s). |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993547632104498 |
---|---|
ctrlnum |
(CKB)3710000000631124 (oapen)https://directory.doabooks.org/handle/20.500.12854/42645 (EXLCZ)993710000000631124 |
collection |
bib_alma |
record_format |
marc |
spelling |
Pedro Viana Baptista auth Cancer nanotheranostics : what have we learned so far? / edited by João Conde, Pedro Viana Baptista, Jesús M. De La Fuente and Furong Tian. Frontiers Media SA 2016 [Lausanne, Switzerland] : Frontiers Media SA, [2015] ©2015 1 online resource (128 pages) : illustrations (chiefly colour); digital file(s). text txt rdacontent computer c rdamedia online resource cr rdacarrier data file rda Frontiers in Chemistry Frontiers Research Topics Includes bibliographical references. After a quarter of century of rapid technological advances, research has revealed the complexity of cancer, a disease intimately related to the dynamic transformation of the genome. However, the full understanding of the molecular onset of this disease is still far from achieved and the search for mechanisms of treatment will follow closely. It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat cancer. In fact, the National Cancer Institute predicts that over the next years, nanotechnology will result in important advances in early detection, molecular imaging, targeted and multifunctional therapeutics, prevention and control of cancer. Nanotechnology offers numerous tools to diagnose and treat cancer, such as new imaging agents, multifunctional devices capable of overcome biological barriers to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, and devices capable of predicting molecular changes to prevent action against precancerous cells... Nevertheless, despite the significant efforts towards the use of nanomaterials in biologically relevant research, more in vivo studies are needed to assess the applicability of these materials as delivery agents. In fact, only a few went through feasible clinical trials. Nanomaterials have to serve as the norm rather than an exception in the future conventional cancer treatments. Future in vivo work will need to carefully consider the correct choice of chemical modifications to incorporate into the multifunctional nanocarriers to avoid activation off-target, side effects and toxicity. Moreover the majority of studies on nanomaterials do not consider the final application to guide the design of nanomaterial. Instead, the focus is predominantly on engineering materials with specific physical or chemical properties. It is imperative to learn how advances in nanosystem’s capabilities are being used to identify new diagnostic and therapy tools driving the development of personalized medicine in oncology; discover how integrating cancer research and nanotechnology modeling can help patient diagnosis and treatment; recognize how to translate nanotheranostics data into an actionable clinical strategy; discuss with industry leaders how nanotheranostics is evolving and what the impact is on current research efforts; and last but not least, learn what approaches are proving fruitful in turning promising clinical data into treatment realities. Also available in print form. In English. Cancer Treatment. Nanostructured materials Health aspects. Nanoparticles Gene Therapy Immunotherapy bioimaging theranostics nanomaterials Drug delivery Nanomedicine Cancer Phototherapy Condé, João, PhD, editor http://viaf.org/viaf/3726161453861264330006 Baptista, Pedro Viana, editor http://viaf.org/viaf/306459607 Fuente, Jesus M. de la, 1975- editor http://viaf.org/viaf/261122336 Tian, Furong, 1971- editor http://viaf.org/viaf/35595301 Print version: Cancer nanotheranostics: what have we learned so far? [Lausanne, Switzerland]: Frontiers Media SA, 2015 288919776X Frontiers research topics. |
language |
English |
format |
eBook |
author |
Pedro Viana Baptista |
spellingShingle |
Pedro Viana Baptista Cancer nanotheranostics : what have we learned so far? / Frontiers in Chemistry Frontiers Research Topics |
author_facet |
Pedro Viana Baptista Condé, João, PhD, Baptista, Pedro Viana, Fuente, Jesus M. de la, 1975- Tian, Furong, 1971- |
author_variant |
p v b pvb |
author2 |
Condé, João, PhD, Baptista, Pedro Viana, Fuente, Jesus M. de la, 1975- Tian, Furong, 1971- |
author2_variant |
j c jc p v b pv pvb j m d l f jmdl jmdlf f t ft |
author2_role |
TeilnehmendeR TeilnehmendeR TeilnehmendeR TeilnehmendeR |
author_sort |
Pedro Viana Baptista |
title |
Cancer nanotheranostics : what have we learned so far? / |
title_sub |
what have we learned so far? / |
title_full |
Cancer nanotheranostics : what have we learned so far? / edited by João Conde, Pedro Viana Baptista, Jesús M. De La Fuente and Furong Tian. |
title_fullStr |
Cancer nanotheranostics : what have we learned so far? / edited by João Conde, Pedro Viana Baptista, Jesús M. De La Fuente and Furong Tian. |
title_full_unstemmed |
Cancer nanotheranostics : what have we learned so far? / edited by João Conde, Pedro Viana Baptista, Jesús M. De La Fuente and Furong Tian. |
title_auth |
Cancer nanotheranostics : what have we learned so far? / |
title_new |
Cancer nanotheranostics : |
title_sort |
cancer nanotheranostics : what have we learned so far? / |
series |
Frontiers in Chemistry Frontiers Research Topics |
series2 |
Frontiers in Chemistry Frontiers Research Topics |
publisher |
Frontiers Media SA Frontiers Media SA, |
publishDate |
2016 2015 |
physical |
1 online resource (128 pages) : illustrations (chiefly colour); digital file(s). Also available in print form. |
isbn |
9782889197767 288919776X |
illustrated |
Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
616 - Diseases |
dewey-full |
616.99406 |
dewey-sort |
3616.99406 |
dewey-raw |
616.99406 |
dewey-search |
616.99406 |
work_keys_str_mv |
AT pedrovianabaptista cancernanotheranosticswhathavewelearnedsofar AT condejoao cancernanotheranosticswhathavewelearnedsofar AT baptistapedroviana cancernanotheranosticswhathavewelearnedsofar AT fuentejesusmdela cancernanotheranosticswhathavewelearnedsofar AT tianfurong cancernanotheranosticswhathavewelearnedsofar |
status_str |
c |
ids_txt_mv |
(CKB)3710000000631124 (oapen)https://directory.doabooks.org/handle/20.500.12854/42645 (EXLCZ)993710000000631124 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Cancer nanotheranostics : what have we learned so far? / |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField noLinkedField |
_version_ |
1787548444831776768 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04703cam a2200577 i 4500</leader><controlfield tag="001">993547632104498</controlfield><controlfield tag="005">20230621140038.0</controlfield><controlfield tag="006">m fo d </controlfield><controlfield tag="007">cr#c|#---|||||</controlfield><controlfield tag="008">191103t20152015sz ad||fob 000-0 eng|d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9782889197767</subfield><subfield code="q">(ebook)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000631124</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/42645</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000631124</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">UkMaJRU</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.99406</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Pedro Viana Baptista</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Cancer nanotheranostics :</subfield><subfield code="b">what have we learned so far? /</subfield><subfield code="c">edited by João Conde, Pedro Viana Baptista, Jesús M. De La Fuente and Furong Tian.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2016</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Lausanne, Switzerland] :</subfield><subfield code="b">Frontiers Media SA,</subfield><subfield code="c">[2015]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (128 pages) :</subfield><subfield code="b">illustrations (chiefly colour); digital file(s).</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">data file</subfield><subfield code="2">rda</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Frontiers in Chemistry</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">After a quarter of century of rapid technological advances, research has revealed the complexity of cancer, a disease intimately related to the dynamic transformation of the genome. However, the full understanding of the molecular onset of this disease is still far from achieved and the search for mechanisms of treatment will follow closely. It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat cancer. In fact, the National Cancer Institute predicts that over the next years, nanotechnology will result in important advances in early detection, molecular imaging, targeted and multifunctional therapeutics, prevention and control of cancer. Nanotechnology offers numerous tools to diagnose and treat cancer, such as new imaging agents, multifunctional devices capable of overcome biological barriers to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, and devices capable of predicting molecular changes to prevent action against precancerous cells... Nevertheless, despite the significant efforts towards the use of nanomaterials in biologically relevant research, more in vivo studies are needed to assess the applicability of these materials as delivery agents. In fact, only a few went through feasible clinical trials. Nanomaterials have to serve as the norm rather than an exception in the future conventional cancer treatments. Future in vivo work will need to carefully consider the correct choice of chemical modifications to incorporate into the multifunctional nanocarriers to avoid activation off-target, side effects and toxicity. Moreover the majority of studies on nanomaterials do not consider the final application to guide the design of nanomaterial. Instead, the focus is predominantly on engineering materials with specific physical or chemical properties. It is imperative to learn how advances in nanosystem’s capabilities are being used to identify new diagnostic and therapy tools driving the development of personalized medicine in oncology; discover how integrating cancer research and nanotechnology modeling can help patient diagnosis and treatment; recognize how to translate nanotheranostics data into an actionable clinical strategy; discuss with industry leaders how nanotheranostics is evolving and what the impact is on current research efforts; and last but not least, learn what approaches are proving fruitful in turning promising clinical data into treatment realities.</subfield></datafield><datafield tag="530" ind1=" " ind2=" "><subfield code="a">Also available in print form.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">In English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer</subfield><subfield code="x">Treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Nanostructured materials</subfield><subfield code="x">Health aspects.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Gene Therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bioimaging</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">theranostics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanomaterials</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Drug delivery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Nanomedicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Phototherapy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Condé, João,</subfield><subfield code="c">PhD,</subfield><subfield code="e">editor</subfield><subfield code="1">http://viaf.org/viaf/3726161453861264330006</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baptista, Pedro Viana,</subfield><subfield code="e">editor</subfield><subfield code="1">http://viaf.org/viaf/306459607</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fuente, Jesus M. de la,</subfield><subfield code="d">1975-</subfield><subfield code="e">editor</subfield><subfield code="1">http://viaf.org/viaf/261122336</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tian, Furong,</subfield><subfield code="d">1971-</subfield><subfield code="e">editor</subfield><subfield code="1">http://viaf.org/viaf/35595301</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Cancer nanotheranostics: what have we learned so far?</subfield><subfield code="d">[Lausanne, Switzerland]: Frontiers Media SA, 2015</subfield><subfield code="z">288919776X</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Frontiers research topics.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-06-25 12:00:32 Europe/Vienna</subfield><subfield code="d">00</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2016-04-12 04:07:06 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338622190004498&Force_direct=true</subfield><subfield code="Z">5338622190004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338622190004498</subfield></datafield></record></collection> |